Immusoft
PrivateLast Round
Grant
Mar 30, 2026
Total Funding Raised
$89.62M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immusoft is a biotechnology company that develops autologous cell therapies utilizing its proprietary Immune System Programming (ISP™) platform to transform patients' B cells into biofactories for the sustained delivery of therapeutic proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immusoft Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Immusoft Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 30, 2026 | ||||
| Grant | Jan 26, 2023 | ||||
| Grant | Nov 29, 2021 | ||||
| Grant | Sep 25, 2020 | ||||
| Series B | Sep 25, 2020 | ||||
Series B | Jan 3, 2019 |
Immusoft Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mesa Verde Venture Partners | Series B |
| EB Research Partnership | Series A |
| Thiel Foundation | Grant |
| NIH RADx | Grant |
| Pathfinder Venture Capital | Series B, Series A |
| Technium | Series A |
| Ikarian Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 40% MoM.
- Mar 30, 2026
$15M grant funding secured.
Immusoft Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immusoft's valuation, stock price, and market status.